Discover
CYTH
Cyclo Therapeutics, Inc.
0.72
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 22.14% | |
| 1y | -49.61% |
0.72
day range
0.72
52 week range
| Open | 0.66 | Prev Close | 0.72 | Low | 0.72 | High | 0.72 | Mkt Cap | N/A |
| Vol | 186.81K | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -0.91 |
| Beta | -0.38 | Short Ratio | 3.82 | Inst. Own | 13.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 0.95 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.17 | -0.26 | -0.09 | -52.94% |
| 2024-08-14 | 2024-06 | -0.14 | -0.21 | -0.07 | -50.00% |
| 2024-05-15 | 2024-03 | -0.2 | -0.15 | 0.05 | 25.00% |
| 2024-03-18 | 2023-12 | 0 | -0.23 | N/A | N/A |
| 2023-11-14 | 2023-09 | 0 | -0.29 | N/A | N/A |
| 2023-08-15 | 2023-06 | 0 | -0.33 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-27 | Maxim Group | Downgrade | Buy | Hold |
| 2024-08-26 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-08-23 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2024-08-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-01 | HC Wainwright & Co. | Upgrade | Buy |
Profile
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-11-14 | CONKLING WILLIAM | Director | 50.23K | Stock Award(Grant) |
| 2024-11-14 | CROSS SHAWN M. | Director | 107.75K | Stock Award(Grant) |
| 2023-10-19 | FINE N SCOTT | Chief Executive Officer | 743.80K | Conversion of Exercise of derivative security |
| 2024-06-02 | OSTRONIC FRANCIS PATRICK | Director | 348.77K | Stock Award(Grant) |
| 2024-11-14 | SHANAHAN WILLIAM S | Director | 148.83K | Stock Award(Grant) |
| 2024-11-14 | SIEGER MARKUS | Director | 382.12K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | EPIQ Capital Group, LLC | 739.43K | 445.13K | 2.57% |
| 2024-09-29 | Vanguard Group Inc | 598.69K | 360.41K | 2.08% |
| 2024-09-29 | Founders Fund V Management, LLC | 480.71K | 289.39K | 1.67% |
| 2024-09-29 | Geode Capital Management, LLC | 152.33K | 91.70K | 0.53% |
| 2024-09-29 | Founders Fund VI Management, LLC | 110.02K | 66.23K | 0.38% |
| 2024-09-29 | Blackrock Inc. | 83.52K | 50.28K | 0.29% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 437.61K | 263.44K | 1.52% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 161.08K | 96.97K | 0.56% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 96.07K | 57.84K | 0.33% |
| 2024-10-30 | iShares Micro Cap ETF | 43.62K | 26.26K | 0.15% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 17.41K | 10.48K | 0.06% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 13.73K | 8.27K | 0.05% |
Split
| Split | Date |
|---|---|
| 1 : 100 | 2020-12-09 |
| 2 : 1 | 2000-05-22 |